Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7246786 | 0.98 | GBA1 (0.63) | GBA1SLC6A4SLC6A2SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL4247331 | 0.98 | GBA1 (0.63) | GBA1SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL20015340 | 0.93 | GBA1 (0.58) | GBA1SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL13330901 | 0.93 | GBA1 (0.58) | GBA1SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL27535617 | 0.91 | GBA1 (0.56) | GBA1SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL6922681 | 0.90 | GBA1 (0.54) | GBA1SLC6A4SLC6A2SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL7512621 | 0.90 | GBA1 (0.54) | GBA1SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL1811296 | 0.89 | GBA1 (0.52) | GBA1SLC6A4SLC6A2SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL3553149 | 0.87 | GBA1 (0.50) | GBA1SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL4966754 | 0.86 | GBA1 (0.50) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768826-B | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2025-05-27 | — | — | CN | claimed |
| CN-116768826-A | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2023-09-19 | — | — | CN | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| CN-1235604-A | Benzoxazole derivatives having affinity for amino acid receptor binding sites | MERCK PATENT GMBH (DE) | 1999-11-17 | — | — | CN | claimed |
| EP-0938485-A1 | BENZOXAZOLE DERIVATIVE WITH AN AFFINITY TO BINDING SITES OF AMINO ACID RECEPTORS | MERCK PATENT GmbH (DE) | 1999-09-01 | — | — | EP | claimed |
| WO-1998018793-A1 | BENZOXAZOLE DERIVATIVE WITH AN AFFINITY TO BINDING SITES OF AMINO ACID RECEPTORS | MERCK PATENT GMBH (DE) | 1998-05-07 | — | — | WO | claimed |
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250339445-A1 | Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke | UNIV EMORY (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12318393-B2 | Modulators of orphan nuclear receptors for NASH and other metabolic disorders | EMORY UNIVERSITY | 2025-06-03 | — | — | US | disclosed |
| CN-116768826-B | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2025-05-27 | — | — | CN | disclosed |
| EP-0288563-B1 | CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 1994-05-11 | — | — | EP | disclosed |
| EP-0572952-A1 | 4-Benzylpiperidine derivatives, a process for preparing them and pharmaceutical compositions containing them | FERRER INTERNACIONAL, S.A. (ES) | 1993-12-08 | — | — | EP | disclosed |
| EP-0514540-A1 | PYRROLO 2,3-d]PYRIMIDINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL PREPARATION COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1992-11-25 | — | — | EP | disclosed |
| US-4921863-A | Cyclic amine derivatives | EISAI CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| EP-0288563-A1 | CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1988-11-02 | — | — | EP | disclosed |
| US-4690931-A | IN TREATMENT OF ANOXIA OR BRAIN DAMAGE | SYNTHELABO (FR) | 1987-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | GBA1 2652/4885SLC6A4 2513/4885SLC6A2 3349/4885 |
| US-12318393-B2 | Modulators of orphan nuclear receptors for NASH and other metabolic disorders | RORA, RORB, RORC | GBA1 1423/4885SLC6A4 3385/4885SLC6A2 3146/4885 |
| US-20250339445-A1 | Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke | RXRA, RXRG, RXRB | GBA1 1540/4885SLC6A4 4730/4885SLC6A2 4261/4885 |
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | PDXK, SLC19A2, NADK | GBA1 1063/4885SLC6A4 434/4885SLC6A2 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.